Salary for Tildra Launch

Are others waiting for offers yet or has the sales force been determined?

 

Biologic drugs targeting IL-23 and IL-17

Drug

Drug company

Drug type

Target

Current status for plaque psoriasis

Ustekinumab (Stelara®, CNTO1275)

Janssen

Human monoclonal antibody

P40 subunit of IL-23 and IL-12

Approved

Briakinumab (ABT 874)

Abbott

Human monoclonal antibody

P40 subunit of IL-23 and IL-12

Terminated

Tildrakizumab (MK-3222)

Merck

Humanized monoclonal antibody

p19 subunit of IL-23

Phase III

BI 655066

Boehringer

Ingelheim

Monoclonal antibody

p19 subunit of IL-23

Phase II

Guselkumab (CNTO 1959)

Janssen

Human IgG1λ monoclonal IL-23 antibody

p19 subunit of IL-23

Phase III

Secukinumab (Cosentyx®, AIN457)

Novartis

Human monoclonal antibody

IL-17A

Approved

Ixekizumab (LY2439821)

Eli Lilly

Humanized monoclonal antibody

IL-17A

Phase III

Brodalumab (AMG 827)

Amgen/AstraZeneca/Valeant

Human monoclonal antibody

IL-17 receptor A

No ongoing studies

ABT-122

AbbVie

Dual variable domain antibody

IL-17 and TNF-α

Phase

 

These products are far from identical. If they were, the innovator would take legal action for patent infringement. Is there enough difference to motivate docs to change? That really is the question.

 

The real FACTS are the POOR/LOW PASI scores and data for TILDRA, pathetic, plus head to head against Enbrel the drug no one talks about any more, OLD DATA dead drug before launch, Tildra is a DOG!

 

I researched the data before interviewing and passed.Tremfya showed 76% of patients had a PASI 90 at week 16. Tildra was 62-64% at week 12. That is a statistical difference, very weak, and it will resonate with Derms. Managed care means nothing as Tremfya has a free program for those not covered by insurance. DOA. Unfortunately this may be a product that only has a handful of prescriptions filled by August. Followed by layoffs and a disaster for all involved. If you are jobless fill your void here while you search. I was Pfizer and would never change for this.

 

Jeez, sounds like just another nail in the coffin for this company.

Is there anything good there? I was contacted by a Sun recruiter but ... it sounds a little sketchy ...

Comments welcomed -

 

Trust your gut on that one. Sketchy is an understatement.

 

company should change it’s name...
Burnt by the Sun

 

Ok, respectfully, enbrel and Humira have PASI scores around 50 and they still hold the market for one reason safety, all biologics work and derms now choose for safety and patient compliance, this drug may have all that plus in office dosing not only increases compliance and the docs can control better and get an office visit out of it, I’m a PA and tremfya has a glorified sample program, not an actual script once um criteria catches up and patients currently on therapy get denied, the window is open, it’s gonna be a dog fight, but Great chances sometimes yield great opportunity, I’m gonna give it a try because I believe

 

Love the FAKE PA post. Tremfya patients are covered 100% even if denied. Nice try. If Sun sticks with it’s usual managed care nightmare, getting 1 script of LOW PERFORMING Tildra will be a miracle!
Reps come to Sun only for the carrot they are wagging, salary, which will be gone in 6 months.

 

Going up against Humira is a death sentence. You Indians will lose your shirts and maybe your sandals too.
Reps won't last 12 months before they either quit in disgrace or get let go.

 

Also Abbvie (Humira) has a superior IL23 coming out....Tildra is history even before launch....enjoy the few months of being led on by Sun....the end is near....

 

Not covered dickhead, comped, anyone can give out free drug to an ineligible patient but when it comes time to get them on insurance if they don’t make the um criteria they get kicked off

 

What are these Tildra reps doing until approval, getting their nails done? Won’t be any different once and IF approved....better sock away that high salary, you’ll need it to supplement your unemployment in a few months...

 

In typical Sun fashion, they will be promoting illegally.

#orangeprisonjumpsuit

 

No derm will prescribe this crap drug...

 

Word on the street with Derms.....NOT even thinking of trying Tildra with the bad data.....better get out your begging cards Tildr reps!

 

also heard a patient died in the tildra study. Good luck with that data

 

DEATH DATA AND HORRIBLE PASI:

reSURFACE 1, at week 12, a PASI75 was acheived in 62% in the 200 mg group and 64% in the 100 mg group compared with 6% in the placebo group (p<0·0001 vs placebo).

In reSURFACE 2, a PASI75 was seen 66% in the 200 mg group, 61% in the 100 mg group, and 48% in the etanercept group compared with 6% in the placebo group.

Serious adverse events were similar and low in all groups in both trials, with only ONE DEATH in reSURFACE 2.